Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Die Highlights vom Kongress des American College of Cardiology 2024

Im April diskutierten die Herz-Kreislauf-Spezialisten aus der ganzen Welt auf dem  Kongress des American College of Cardiology (ACC) u.a. neue Therapieansätze bei akutem Myokardinfarkt, koronarer Herzerkrankung, kardiogenem Schock oder Aortenklappenstenose. In unserem Kongress-Dossier haben wir für Sie Berichte über die „Late-Breaking Trials“ und andere wichtige Studien zusammengestellt. 
Erweiterte Suche
Anmelden
nach oben
PharmacoEconomics
Erschienen in: PharmacoEconomics 12/2001

01.12.2001 | Review Article

Incremental Cost Effectiveness of Prophylaxis for Cytomegalovirus Disease in Patients with AIDS

verfasst von: John H. Kempen, Kevin D. Frick, Douglas A. Jabs

Erschienen in: PharmacoEconomics | Ausgabe 12/2001

Einloggen, um Zugang zu erhalten

Abstract

Cytomegalovirus (CMV) disease, an opportunistic complication in patients with AIDS, causes substantial morbidity and has high treatment costs. Although prevention of this disease is highly desirable, incremental cost-effectiveness estimates for proposed prophylactic strategies in the era prior to the availability of highly active antiretroviral therapy (HAART) were unfavourable relative to other specific antimicrobial prophylactic strategies in patients with AIDS. With the availability of HAART, several inputs upon which previous estimates of the incremental cost-effectiveness ratio for anti-CMV prophylaxis were based have probably changed substantially. To assess the incremental cost effectiveness of prophylaxis in the HAART era, data are needed on visual outcomes and utility for patients with CMV retinitis and AIDS, on better strategies for identifying subpopulations at high risk for CMV disease and on the prophylactic efficacy of valganciclovir. Cost-effectiveness analysis could potentially contribute by exploring thresholds of population risk, prophylactic effectiveness, and drug pricing in order to identify conditions under which prophylaxis for CMV disease in patients with AIDS could potentially become cost effective.
Literatur
1.
Hoover DR, Saah AJ, Bacellar H, et al. Clinical manifestations of AIDS in the era of pneumocystis prophylaxis. N Engl J Med 1993; 329: 1922–6PubMedCrossRef
2.
Gallant JE, Moore RD, Richman DD, et al. Incidence and natural history of cytomegalovirus disease in patients with advanced human immunodeficiency virus disease treated with zidovudine. The Zidovudine Epidemiology Study Group. J Infect Dis 1992; 166: 1223–7PubMedCrossRef
3.
Hoover DR, Peng Y, Saah A, et al. Occurrence of cytomegalovirus retinitis after human immunodeficiency virus immunosuppression. Arch Ophthalmol 1996; 114: 821–7PubMedCrossRef
4.
Pertel P, Hirschtick R, Phair J, et al. Risk of developing cytomegalovirus retinitis in persons infected with the human immunodeficiency virus. J Acquir Immune Defic Syndr 1992; 5: 1069–74PubMed
5.
Jabs DA. Ocular manifestations of HIV infection. Trans Am Ophthalmol Soc 1995; 93: 623–83PubMed
6.
Moore RD, Chaisson RE. Cost-utility analysis of prophylactic treatment with oral ganciclovir for cytomegalovirus retinitis. J Acquir Immune Defic Syndr 1997; 16: 15–21CrossRef
7.
Varani S, Spezzacatena P, Manfredi R, et al. The incidence of cytomegalovirus (CMV) antigenemia and CMV disease is reduced by highly active antiretroviral therapy. Eur J Epidemiol 2000; 16: 433–7PubMedCrossRef
8.
Labetoulle M, Goujard C, Frau E, et al. Cytomegalovirus retinitis in advanced HIV-infected patients treated with protease inhibitors: incidence and outcome over 2 years. J Acquir Immune Defic Syndr 1999; 22: 228–34PubMed
9.
Jalali S, Reed JB, Mizoguchi M, et al. Effect of highly active antiretroviral therapy on the incidence of HIV-related cytomegalovirus retinitis and retinal detachment. AIDS Patient Care STDS 2000; 14: 343–6PubMedCrossRef
10.
Jacobson MA, Mills J. Serious cytomegalovirus disease in the acquired immunodeficiency syndrome (AIDS): clinical findings, diagnosis, and treatment. Ann Intern Med 1988; 108: 585–94PubMed
11.
12.
Goodgame RW. Gastrointestinal cytomegalovirus disease. Ann Intern Med 1993; 119: 924–35PubMed
13.
Morgellow S, Cho ES, Nielson S, et al. Cytomegalovirus encephalitis in patients with the acquired immune deficiency syndrome: an autopsy study of 30 cases and a review of the literature. Hum Pathol 1987; 18: 289–97CrossRef
14.
Thorne JE, Jabs DA, Vitale S, et al. Catheter complications in AIDS patients treated for cytomegalovirus retinitis. AIDS 1998; 12: 2321–7PubMedCrossRef
15.
Deayton JR, Wilson P, Sabin CA, et al. Changes in the natural history of cytomegalovirus retinitis following the introduction of highly active antiretroviral therapy. AIDS 2000; 14: 163–1170CrossRef
16.
MacDonald JC, Torriani FJ, Morse LS, et al. Lack of reactivation of cytomegalovirus (CMV) retinitis after stopping CMV maintenance therapy in AIDS patients with sustained elevations in CD4 T cells in response to highly active antiretroviral therapy. J Infect Dis 1998; 177: 1182–7PubMedCrossRef
17.
Jabs DA, Bolton SG, Dunn JP, et al. Discontinuing anticytomegalovirus therapy in patients with immune reconstitution after combination antiretroviral therapy. Am J Ophthalmol 1998; 126: 817–22PubMedCrossRef
18.
Whitcup SM, Fortin E, Lindblad AS, et al. Discontinuation of anticytomegalovirus therapy in patients with HIV infection and cytomegalovirus retinitis. JAMA 1999; 282: 1633–7PubMedCrossRef
19.
MacDonald JC, Karavellas MP, Torriani FJ, et al. Highly active antiretroviral therapy-related immune recovery in AIDS patients with cytomegalovirus retinitis. Ophthalmology 2000; 107: 877–81PubMedCrossRef
20.
Davis JL, Tabandeh H, Feuer WJ, et al. Effect of potent antiretroviral therapy on recurrent cytomegalovirus retinitis treated with the ganciclovir implant. Am J Ophthalmol 1999; 127: 283–7PubMedCrossRef
21.
Karavellas MP, Plummer DJ, MacDonald JC, et al. Incidence of immune recovery vitritis in cytomegalovirus retinitis patients following institution of successful highly active antiretroviral therapy. J Infect Dis 1999; 179: 697–700PubMedCrossRef
22.
Spector SA, Weingeist T, Pollard RB, et al. A randomized, controlled study of intravenous ganciclovir therapy for cytomegalovirus peripheral retinitis in patients with AIDS. AIDS Clinical Trials Group and Cytomegalovirus Cooperative Study Group. J Infect Dis 1993; 168: 557–63PubMedCrossRef
23.
Studies of Ocular Complications of AIDS Research Group, in collaboration with the AIDS Clinical Trials Group. Foscarnetganciclovir Cytomegalovirus Retinitis Trial. 4. Visual outcomes. Ophthalmology 1994; 101: 1250–61
24.
Palestine AG, Polis MA, De Smet MD, et al. A randomized, controlled trial of foscarnet in the treatment of cytomegalovirus retinitis in patients with AIDS. Ann Intern Med 1991; 115: 665–73PubMed
25.
Studies of Ocular Complications of AIDS Research Group, in collaboration with the AIDS Clinical Trials Group. Parenteral cidofovir for cytomegalovirus retinitis in patients with AIDS: the HPMPC peripheral cytomegalovirus trial. A randomized, controlled trial. Ann Intern Med 1997; 126: 264–74
26.
Lalezari JP, Stagg RJ, Kuppermann BD, et al. Intravenous cidofovir for peripheral cytomegalovirus retinitis in patients with AIDS: a randomized, controlled trial. Ann Intern Med 1997; 126: 257–63PubMed
27.
Martin DF, Parks DJ, Mellow SD, et al. Treatment of cytomegalovirus retinitis with an intraocular sustained-release ganciclovir implant. A randomized controlled trial. Arch Ophthalmol 1994; 112: 1531–9PubMedCrossRef
28.
Musch DC, Martin DF, Gordon JF, et al. Treatment of cytomegalovirus retinitis with a sustained-release ganciclovir implant. The Ganciclovir Implant Study Group. N Engl J Med 1997; 337: 83–90PubMedCrossRef
29.
Martin DF, Kuppermann BD, Wolitz RA, et al. Oral ganciclovir for patients with cytomegalovirus retinitis treated with a ganciclovir implant. Roche Ganciclovir Study Group. N Engl J Med 1999; 340: 1063–70PubMedCrossRef
30.
Cantrill HL, Henry K, Melroe NH, et al. Treatment of cytomegalovirus retinitis with intravitreal ganciclovir: long-term results. Ophthalmology 1989; 96: 367–74PubMed
31.
Heinemann MH. Long-term intravitreal ganciclovir therapy for cytomegalovirus retinitis. Arch Ophthalmol 1989; 107: 1767–72PubMedCrossRef
32.
Ussery FM III, Gibson SR, Conklin RH, et al. Intravitreal ganciclovir in the treatment of AIDS-associated cytomegalovirus retinitis. Ophthalmology 1988; 95: 640–8PubMed
33.
Diaz-Llopis M, Espana E, Munoz G, et al. High dose intravitreal foscarnet in the treatment of cytomegalovirus retinitis in AIDS. Br J Ophthalmol 1994; 78: 120–4PubMedCrossRef
34.
Kirsch LS, Arevalo JF, Chavez de la Paz E, et al. Intravitreal cidofovir (HPMPC) treatment of cytomegalovirus retinitis in patients with acquired immune deficiency syndrome. Ophthalmology 1995; 102: 533–42PubMed
35.
de Smet MD, Meenken CJ, van den Horn GJ. Fomivirsen: a phosphorothioate oligonucleotide for the treatment of CMV retinitis. Ocul Immunol Inflamm 1999; 7: 189–98PubMedCrossRef
36.
Drew WL, Ives D, Lalezari JP, et al. Oral ganciclovir as maintenance treatment for cytomegalovirus retinitis in patients with AIDS. N Engl J Med 1995; 333: 615–20PubMedCrossRef
37.
Martin DF, Dunn JP, Davis JL, et al. Use of the ganciclovir implant for the treatment of cytomegalovirus retinitis in the era of potent antiretroviral therapy: recommendations of the International AIDS Society-USA panel. Am J Ophthalmol 1999; 127: 329–39PubMedCrossRef
38.
Brown F, Banken L, Saywell K, et al. Pharmacokinetics of valganciclovir and ganciclovir following multiple oral dosages of valganciclovir in HIV- and CMV-seropositive volunteers. Clin Pharmacokinet, 1999; 37: 167–76PubMedCrossRef
39.
Lucas GM, Chaisson RE, Moore RD. Highly active antiretroviral therapy in a large urban clinic: risk factors for virologic failure and adverse drug reactions. Ann Intern Med 1999; 131: 81–7PubMed
40.
Pradier C, Pesce A, Carrieri P, et al. Effect of indinavir and higher CD4+ T-cell count on viral load response after 6 months of highly active antiretroviral therapy. Clin Ther 1999; 21: 1313–20PubMedCrossRef
41.
Grabar S, Le Moing V, Goujard C, et al. Clinical outcome of patients with HIV-1 infection according to immunologic and virologic response after 6months of highly active antiretroviral therapy. Ann Intern Med 2000; 133: 401–10PubMed
42.
D’Arminio MA, Testori V, Adorni F, et al. CD4 cell counts at the third month of HAART may predict clinical failure. AIDS 1999; 13: 1669–76CrossRef
43.
Feinberg JE, Hurwitz S, Cooper D, et al. A randomized, double-blind trial of valaciclovir prophylaxis for cytomegalovirus disease in patients with advanced human immunodeficiency virus infection. J Infect Dis 1998; 177: 48–56PubMedCrossRef
44.
Spector SA, McKinlay GF, Lalezari JP, et al. Oral ganciclovir for the prevention of cytomegalovirus disease in persons with AIDS. Roche Cooperative Oral Ganciclovir Study Group. N Engl J Med 1996; 334: 146–50CrossRef
45.
Brosgart CL, Louis TA, Hillman DW, et al. A randomized, placebo-controlled trial of the safety and efficacy of oral ganciclovir for prophylaxis of Cytomegalovirus disease in HIV-infected individuals. Terry Beirn Community Programs for Clinical Research on AIDS. AIDS 1998; 12: 269–77PubMedCrossRef
46.
Spector SA, Hsia K, Crager M, et al. Cytomegalovirus (CMV) DNA load is an independent predictor of CMV disease and survival in advanced AIDS. J Virol 1999; 73: 7027–30PubMed
47.
Emery VC, Sabin C, Feinberg JE, et al. Quantitative effects of valacyclovir on the replication of cytomegalovirus (CMV) in persons with advanced human immunodeficiency virus disease: baseline CMV load dictates time to disease and survival. The AIDS Clinical Trials Group 204/Glaxo Wellcome 123-014 International CMV Prophylaxis Study Group. J Infect Dis 1999; 180: 695–701PubMedCrossRef
48.
Van der Meer JT, Drew WL, Bowden RA, et al. Summary of the international consensus symposium on advances in the diagnosis, treatment and prophylaxis and cytomegalovirus infection. Antiviral Res 1996; 32: 119–40PubMedCrossRef
49.
Nichols WG, Boeckh M. Pre-emptive therapy based on markers of CMV viremia has been useful in the transplant setting. J Clin Virol 2000; 16: 25–40PubMedCrossRef
50.
Centers for Disease Control and Prevention. 1999 USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus: U.S. Public Health Service (UPSHS) and Infectious Diseases Society of America (IDSA). MMWR Morb Mort Wkly Rep 1999; 48: 1–66
51.
Liu GG, Hay J. An economic cost analysis of oral ganciclovir prophylaxis for the prevention of CMV disease. Pharm Res 2000; 17: 911–9PubMedCrossRef
52.
Rose DN, Sacks HS. Cost-effectiveness of cytomegalovirus (CMV) disease prevention in patients with AIDS: oral ganciclovir and CMV polymerase chain reaction testing. AIDS 1997; 11 (7): 883–7PubMedCrossRef
53.
Freedberg KA, Scharfstein JA, Seage GR III, et al. The costeffectiveness of preventing AIDS-related opportunistic infections. JAMA 1996; 279: 130–6CrossRef
54.
Paltiel AD, Scharfstein JA, Seage III GR, et al. A Monte Carlo simulation of advanced HIV disease: application to prevention of CMV infection. Med Decis Making 1998; 18 (2 Suppl.): S93–105CrossRef
55.
Paltiel AD, Goldie SJ, Losina E, et al. Pre-evaluation of clinical trial data: the case of pre-emptive cytomegalovirus therapy in patients with human immunodeficiency virus. Clin Infect Dis 2001; 32: 783–93PubMedCrossRef
56.
Gold MR, Siegel JE, Russel LB, et al., editors. Cost-effectiveness in health and medicine. New York (NY): Oxford University Press, 1996
57.
Jaton KR, Muheim CR, Barbani MT, et al. Detection of CMV DNA in peripheral blood leukocytes as a long-range harbinger of CMV disease in HIV-infected patients. Swiss HIV Cohort Study. Ocul Immunol Inflam 1999; 7: 147–57CrossRef
58.
Chevret S, Scieux C, Garrait V, et al. Usefulness of the cytomegalovirus (CMV) antigenemia assay for predicting the occurrence of CMV disease and death in patients with AIDS. Clin Infect Dis 1999; 28: 758–63PubMedCrossRef
59.
Wattanamano P, Clayton JL, Kopicko JJ, et al. Comparison of three assays for cytomegalovirus detection in AIDS patients at risk for retinitis. J Clin Microbiol 2000; 38: 727–32PubMed
60.
Blank BS, Meenhorst PL, Mulder JW, et al. Value of different assays for detection of human cytomegalovirus (HCMV) in predicting the development of HCMV disease in human immunodeficiency virus-infected patients. J Clin Microbiol 2000; 38: 563–9PubMed
61.
Mellors JW, Munoz A, Giorgi JV, et al. Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med 1997; 126: 946–54PubMed
62.
Kempen JH, Jabs DA, Dunn JP, et al. Retinal detachment risk in cytomegalovirus retinitis related to the acquired immune deficiency syndrome. Arch Ophthalmol 2001; 119: 33–40PubMed
63.
Salmon-Ceron D, Mazeron MC, Chaput S, et al. Plasma cytomegalovirus DNA, pp65 antigenaemia and a low CD4 cell count remain risk factors for cytomegalovirus disease in patients receiving highly active antiretroviral therapy. AIDS 2000; 8: 1041–9CrossRef
64.
Youle MS, Gazzard BG, Johnson MA, et al. Effects of high-dose oral acyclovir on herpesvirus disease and survival in patients with advanced HIV disease: a double-blind, placebo-controlled study. European-Australian Acyclovir Study Group. AIDS 1994; 8: 641–9PubMedCrossRef
65.
66.
Metadaten
Titel
Incremental Cost Effectiveness of Prophylaxis for Cytomegalovirus Disease in Patients with AIDS
verfasst von
John H. Kempen
Kevin D. Frick
Douglas A. Jabs
Publikationsdatum
01.12.2001
Verlag
Springer International Publishing
Erschienen in
PharmacoEconomics / Ausgabe 12/2001
Print ISSN: 1170-7690
Elektronische ISSN: 1179-2027
DOI
https://doi.org/10.2165/00019053-200119120-00002

Weitere Artikel der Ausgabe 12/2001

PharmacoEconomics 12/2001 Zur Ausgabe

Review Article

Accounting for Noncompliance in Pharmacoeconomic Evaluations

Adis Pharmacoeconomic Drug Evaluation

Paclitaxel

Original Research Article

Direct Costs of Schizophrenia in Italian Community Psychiatric Services

Original Research Article

Economic Evaluation of Collagenase-Containing Ointment and Hydrocolloid Dressing in the Treatment of Pressure Ulcers